ClinicalTrials.gg
RecruitingNCT06531681Updated Feb 13, 2025

Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)

An observational study in Overall Response Rate, Oncology and Radiation Toxicity, sponsored by The Second Affiliated Hospital of Hainan Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by The Second Affiliated Hospital of Hainan Medical University · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.

Read the detailed description

Primary endpoint:

  • Overall response rate (ORR) : It refers to the proportion of patients whose tumor volume reduction reaches the pre-specified value and can maintain the minimum time requirement, which is a Complete Response (CR) and a partial response (PR). Partial Response) sum of the proportions.

Secondary points:

  • Progression-free Survival (PFS) : the time from the start of treatment until objective tumor Progression or all-cause death of the patient.
  • Disease Control Rate (DCR) : The percentage of patients whose cancer shrinks or remains stable over time.
  • Overall Survival (OS) : the time from the start of treatment to all-cause death.
  • Incidence of adverse reactions: toxicity according to Common Toxicity Criteria for Adverse Events (CTCAE).
  • Quality of life: The EORTC Quality of Life measure -QLQ-C30-(V3.0) was used, and the higher the score, the higher the quality of life.
  • Dosimetric parameters: include gross target volume(GTV), clinical target volume(CTV),internal target volume(ITV),planning target volume(PTV),γ-passing rate,and limited dose of organs at risk (including average dose, maximum dose, etc.)
02

Conditions studied

  • Overall Response Rate
  • Oncology
  • Radiation Toxicity
  • Quality of Life
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

The Second Affiliated Hospital of Hainan Medical University is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients will receive or have completed imaging or treatment procedures at MR-Linac, Department of Radiotherapy, Second Affiliated Hospital of Hainan Medical University, age 18-75 years, male or female, ECOG score 0-2, life expectancy > 6 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are undergoing or have undergone imaging or treatment at the MR linac;
  • Age 18-75 years, male or female;
  • score 0-2, > 6 months;
  • Patients provide written .

Exclusion criteria

Exclusion Criteria:

  • to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI;
  • The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy;
  • Acute inflammatory disease requiring systemic therapy;
  • The presence of active infectious disease;
  • Pregnant women, nursing mothers, and patients planning to have children during the study period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Interventions

  • DeviceMR-Linac

    Radiation therapy with the MR-Linac

06

What researchers measure

Primary outcomes

  1. overall response rate

    The proportion of patients whose tumor volume reduction reached the predetermined value and maintained the minimum time limit requirement was the sum of CR (Complete Response) and PR (Partial Response) proportions.

    Time frame: 3months, 6months,12months,24months,36months,60months

Secondary outcomes

  1. Progression-Free Survival

    The time from the start of treatment until objective tumor Progression or patient all-cause death

    Time frame: 3months, 6months,12months,24months,36months,60months

  2. Disease Control Rate

    The percentage of patients whose cancer shrinks or remains stable over time

    Time frame: 3months, 6months,12months,24months,36months,60months

  3. Overall survival

    Overall survival of participating patients will be obtained from the hospital information systems

    Time frame: 3months, 6months,12months,24months,36months,60months

  4. Incidence of adverse reactions

    Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary

    Time frame: 3months, 6months,12months,24months

  5. Patient reported Health related quality of life (HRQoL)

    Patient reported health related quality of life is captured through a questionnaire the Generic European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. It is a core scale applicable to all cancer patients. It contains a total of 30 items, items 1 to 28 are divided into 4 grades and scored 1 to 4 points, items 29 and 30 are divided into 7 grades and scored 1 to 7 points. The 30 entries are divided into 15 domains, including 5 functional domains (i.e., somatic, role, cognitive, emotional, and social), 3 symptom domains (i.e., fatigue, pain, nausea, and vomiting), 1 quality of life domain, and 6 single entries/domains. A high score on functional or global health status scale represents a high/healthy level of functioning.

    Time frame: 3months,6months,12months,24months

  6. Dosimetric parameters:dose of target volume(TV)

    Dose of target volume(TV)includes gross target volume(GTV),clinical target volume(CTV),internal target volume(ITV) and planning target volume(PTV),Measured by cGy.

    Time frame: During Radiotherapy

  7. Dosimetric parameters:OAR

    Limited dose of organ at risk(OAR) ,includes mean dose(Dmean), maximum dose(Dmax)and minimum dose(Dmin),Measured by cGy. Volume dose limitation,Measured by percent(%),for example, lung V20≤30%.

    Time frame: During Radiotherapy

  8. Dosimetric parameters:γ passing rate

    The gamma passing rate evaluates the coincidence between the calculated and measured dose distributions by utilizing the percent dose difference (DD) and distance to agreement.

    Time frame: During Radiotherapy

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2028, 64 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 64 months is close to that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Aug 1, 2024
StartActual
Aug 19, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06531681
Lead sponsor
The Second Affiliated Hospital of Hainan Medical University
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Aug 19, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 13, 2025

Study contacts

junnv xu, doctor
Contact
xujunnv@sina.com
18208946196
yuecan zeng, doctor
Contact
wellyy2005@hainmc.edu.cn
19946610752
yuecan zeng, doctor
principal investigator · The Second Affiliated Hospital of Hainan Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion